⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

$1M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

Published 29/12/2023, 11:36
© Reuters.  $1M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
SRAX
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

The Dow Jones index closed higher by over 50 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

SRAX

  • The Trade: SRAX, Inc. (OTC: SRAX) CEO Christopher Miglino acquired a total of 15,000 shares an average price of $0.05. To acquire these shares, it cost around $750.
  • What’s Happening: The company’s stock dipped 77% over the past month.
  • What SRAX Does: SRAX Inc is a financial technology company that unlocks data and insights for publicly traded companies.
VerifyMe
  • The Trade: VerifyMe, Inc. (NASDAQ: VRME) CEO Adam Stedham acquired a total of 14,441 shares at an average price of $1.04. To acquire these shares, it cost around $15,019.
  • What’s Happening: VerifyMe board approved a share repurchase program of up to $500,000.
  • What VerifyMe Does: VerifyMe Inc is a technology solutions company based in the United States. It markets a broad patent portfolio that includes patents in the field of authenticating products, people, and financial transactions.
Check This Out: Wall Street's Most Accurate Analysts Say Buy These 3 Industrials Stocks With Over 3% Dividend Yields

Annexon

  • The Trade: Annexon, Inc. (NASDAQ: ANNX) Director Muneer A Satter acquired a total of 350,000 shares at an average price of $2.88. The insider spent around $1.01 million to buy those shares.
  • What’s Happening: Annexon reported pricing of $125 million public offering of common stock.
  • What Annexon Does: Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye.

Don’t forget to check out our premarket coverage here

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.